Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cartesian Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Cartesian Therapeutics, Inc.’s stock price such as:

• Cartesian Therapeutics, Inc.’s current stock price and volume
• Why Cartesian Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for RNAC from analysts
• RNAC’s stock price momentum as measured by its relative strength

About Cartesian Therapeutics, Inc. (RNAC)

Before we jump into Cartesian Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.

Want to learn more about Cartesian Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cartesian Therapeutics, Inc..

Cartesian Therapeutics, Inc.’s Stock Price as of Market Close

As of December 11, 2025, 3:59 PM, CST, Cartesian Therapeutics, Inc.’s stock price was $8.470.

Cartesian Therapeutics, Inc. is up 7.9% from its previous closing price of $7.850.

During the last market session, Cartesian Therapeutics, Inc.’s stock traded between $7.735 and $8.620. Currently, there are approximately 26.00 million shares outstanding for Cartesian Therapeutics, Inc..

Cartesian Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cartesian Therapeutics, Inc. Stock Price History

Cartesian Therapeutics, Inc.’s (RNAC) price is currently up 13.08% so far this month.

During the month of December, Cartesian Therapeutics, Inc.’s stock price has reached a high of $8.620 and a low of $6.530.

Over the last year, Cartesian Therapeutics, Inc. has hit prices as high as $24.030 and as low as $5.980. Year to date, Cartesian Therapeutics, Inc.’s stock is down 52.71%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cartesian Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 10, 2025, there were 0 analysts who downgraded Cartesian Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cartesian Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cartesian Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cartesian Therapeutics, Inc. (RNAC) by visiting AAII Stock Evaluator.

Relative Price Strength of Cartesian Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 10, 2025, Cartesian Therapeutics, Inc. has a weighted four-quarter relative price strength of -25.40%, which translates to a Momentum Score of 6 and is considered to be Very Weak.

Want to learn more about how Cartesian Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cartesian Therapeutics, Inc. Stock Price: Bottom Line

As of December 11, 2025, Cartesian Therapeutics, Inc.’s stock price is $8.470, which is up 7.9% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cartesian Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.